Details for Patent: 9,540,382
✉ Email this page to a colleague
Which drugs does patent 9,540,382 protect, and when does it expire?
Patent 9,540,382 protects IMBRUVICA and is included in one NDA.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-one patent family members in thirty-one countries.
Summary for Patent: 9,540,382
| Title: | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
| Abstract: | Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
| Inventor(s): | Purro; Norbert (Los Gatos, CA), Smyth; Mark (Foster City, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 14/405,317 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,540,382 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; Dosage form; |
Drugs Protected by US Patent 9,540,382
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,540,382
| PCT Information | |||
| PCT Filed | June 03, 2013 | PCT Application Number: | PCT/US2013/043888 |
| PCT Publication Date: | December 12, 2013 | PCT Publication Number: | WO2013/184572 |
International Family Members for US Patent 9,540,382
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 092844 | ⤷ Try a Trial | |||
| Argentina | 118108 | ⤷ Try a Trial | |||
| Australia | 2013271918 | ⤷ Try a Trial | |||
| Australia | 2016250445 | ⤷ Try a Trial | |||
| Australia | 2018211201 | ⤷ Try a Trial | |||
| Australia | 2018211216 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
